WO2024078507A1 - Utilisation d'ergostérol dans la préparation d'un médicament pour la prévention et le traitement d'ulcères gastriques - Google Patents
Utilisation d'ergostérol dans la préparation d'un médicament pour la prévention et le traitement d'ulcères gastriques Download PDFInfo
- Publication number
- WO2024078507A1 WO2024078507A1 PCT/CN2023/123828 CN2023123828W WO2024078507A1 WO 2024078507 A1 WO2024078507 A1 WO 2024078507A1 CN 2023123828 W CN2023123828 W CN 2023123828W WO 2024078507 A1 WO2024078507 A1 WO 2024078507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergosterol
- gastric
- drug
- preventing
- gastric ulcers
- Prior art date
Links
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 title claims abstract description 55
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 title claims abstract description 55
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 title claims abstract description 55
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 title claims abstract description 55
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 title claims abstract description 55
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000002496 gastric effect Effects 0.000 claims abstract description 13
- 230000028327 secretion Effects 0.000 claims abstract description 7
- 210000003097 mucus Anatomy 0.000 claims abstract description 6
- 201000005917 gastric ulcer Diseases 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 229960003174 lansoprazole Drugs 0.000 description 6
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- -1 V346 Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol group Chemical group [C@@H]1(CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)\C=C\[C@H](C)C(C)C DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the invention belongs to the technical field of biomedicine, and particularly relates to the application of ergosterol in the preparation of medicines for preventing and treating gastric ulcers.
- Gastric ulcer is a common clinical disease. There are many factors that cause gastric ulcer, including drugs and diet (excessive drinking, use of nonsteroidal anti-inflammatory drugs, etc.), mental factors (high life pressure, high mental tension, etc.), genetic factors, etc. If gastric ulcer is not treated in time, it may also induce upper gastrointestinal bleeding, gastric perforation, pyloric obstruction and even gastric cancer. Clinically, proton pump inhibitors are often used to treat gastric ulcers. The treatment time is usually 1 to 2 months. Long-term use of proton pump inhibitors will inhibit the secretion of pepsin and also have a certain negative impact on the acid-secreting glands. Accelerating the recovery of gastric ulcers and reducing the use of proton pump inhibitors are one of the important clinical problems to be solved.
- Ergosterol also known as ergosterol, is a white or colorless shiny small leaf crystal or white crystalline powder. As an important component of fungal cell membrane, ergosterol has a stable structure and strong specificity. It is more representative than glucosamine for measuring biomass. Due to its unique physiological effects, ergosterol is widely used in drug development, but there is no record of ergosterol in the treatment of gastric ulcers.
- the purpose of the present invention is to enrich the medical uses of ergosterol and effectively prevent and treat gastric ulcer.
- the present invention provides the use of ergosterol in preparing a drug for preventing and treating gastric ulcer.
- the ergosterol is the only active ingredient.
- the triggering factors of gastric ulcer include alcohol and/or acid.
- the alcohol is anhydrous ethanol.
- the acid is acetic acid.
- the target of the drug is Ror ⁇ protein.
- the prevention and treatment of gastric ulcer includes promoting gastric mucus secretion and/or activating gastric stem cells.
- the dosage form of the drug includes any one of powder, injection, capsule, tablet, pill, granule and oral solution.
- the present invention also provides a medicine for preventing and treating gastric ulcer, which comprises ergosterol and medically acceptable auxiliary materials.
- the ergosterol is used as the only active ingredient of the drug.
- the present invention also provides a method for preventing and treating gastric ulcer, comprising administering ergosterol by intragastric administration at a dosage of 50-500 mg ergosterol/d/person.
- the present invention provides the use of ergosterol in the preparation of a drug for preventing and treating gastric ulcers.
- the ergosterol of the present invention can promote the secretion of gastric mucus, resist gastric ulcers caused by anhydrous ethanol, and promote the recovery of gastric ulcers caused by acetic acid, and can be used for preventing and treating gastric ulcers.
- FIG1 shows the preventive effect of ergosterol on acute gastric ulcer in rats induced by anhydrous ethanol
- FIG2 shows the therapeutic effect of ergosterol on gastric ulcer in mice induced by acetic acid
- FIG3 is the molecular docking result of ergosterol and RoR ⁇ on gastric stem cells
- FIG4 shows the change of the root mean square deviation (RMSD) of the complex over time during the molecular dynamics simulation.
- the invention provides application of ergosterol in preparing medicine for preventing and treating gastric ulcer.
- the ergosterol described in the present invention is a type of component with cyclopentane polyhydrophenanthrene as the parent nucleus, and has a similar skeleton to corticosteroids.
- the specific structural formula is as follows:
- the purity of the ergosterol monomer is preferably ⁇ 99%. There is no strict requirement on the source, regular purchase is sufficient.
- the dosage form of the drug is preferably a medically acceptable dosage form; the medically acceptable dosage form preferably includes any one of powder, injection, capsule, tablet and oral solution.
- the inducement of gastric ulcer preferably includes alcohol and/or acid; the alcohol is preferably anhydrous ethanol; and the acid is preferably acetic acid.
- the ergosterol of the present invention has a similar skeleton to corticosteroids, the effects of ergosterol and corticosteroids are different: corticosteroids increase gastric acid secretion, inhibit gastric mucus secretion, and promote the occurrence of gastric ulcers; ergosterol can promote the secretion of gastric mucus, resist gastric ulcers caused by anhydrous ethanol, and promote the recovery of experimental gastric ulcers caused by acetic acid. Ergosterol can effectively prevent and treat gastric ulcers.
- the results of the embodiment show that according to the dosage of 10-40 mg ergosterol/kg mouse and 50-500 mg ergosterol/d/person, gastric ulcers can be effectively prevented and treated.
- the present invention also provides a drug for preventing and treating gastric ulcers, wherein the active ingredient of the drug includes ergosterol.
- the ergosterol of the present invention also includes a drug with the function of preventing and treating gastric ulcers, which is composed of ergosterol as a raw material and an auxiliary material or auxiliary component allowed in the drug.
- the present invention has no strict requirements on the specific type of the auxiliary material, and it can be selected according to the conventional dosage form of the drug.
- Ergosterol purchased from McLean
- lansoprazole purchased from Jiangsu Renhe Pharmaceutical Co., Ltd.
- 48 SD healthy rats 200-220 g (purchased from Zhuhai Baishitong Biotechnology Co., Ltd.); 36 C57BL/6 healthy mice, 18-22 g (purchased from Guangzhou Ruige Biotechnology Co., Ltd.).
- the healthy rats in step 1 were randomly divided into a control group, a model group, a lansoprazole group, a low-dose ergosterol group, a medium-dose ergosterol group, and a high-dose ergosterol group, with 8 healthy rats in each group.
- the rats were given medication according to the method in Table 1. During the medication period, the diet, drinking water and other conditions of the rats in each group were the same.
- the drugs were continuously administered for 7 days according to Table 1.
- the rats in the model group, lansoprazole group, low-dose ergosterol group, medium-dose ergosterol group, and high-dose ergosterol group were gavaged with 1 mL of anhydrous ethanol; the rats in the control group were gavaged with 1 mL of purified water.
- the rats were killed by overdose anesthesia, and the gastric tissues of the rats were obtained and dissected to observe the ulcers in the gastric tissues of the rats.
- the ulcer area was calculated by grading using ImageJ. The results are shown in Figure 1 and Table 2.
- the healthy mice in step 1 were randomly divided into a control group and an experimental group, with 6 healthy mice in the control group and 30 healthy mice in the experimental group.
- the abdominal cavity of the control group was opened and randomly closed without treatment; the abdominal cavity of the experimental group was opened to expose the whole stomach, and acetic acid was dipped into a 2 mm diameter glass capillary, which was then poked into the stomach body for a total of 20 seconds.
- the abdominal cavity was closed after waiting for 1 minute. After the stomach was opened, a whitish ulcer surface could be seen, indicating that the gastric ulcer model was successfully constructed.
- mice On the second day after the model was established, the experimental mice were randomly divided into 5 groups, namely, model group, lansoprazole group, low-dose ergosterol group, medium-dose ergosterol group and high-dose ergosterol group, with 6 mice in each group.
- the drugs were administered according to the method in Table 3. During the drug administration period, the diet, drinking water and other conditions of each group of rats were the same.
- mice in each test group were killed, and the gastric tissues of the mice were obtained and dissected to observe the ulcers in the gastric tissues of the mice.
- the ulcer area was calculated by grading using ImageJ. The results are shown in Figure 2 and Table 4.
- mice in the control group had no gastric ulcers, while the model group had large-area gastric ulcers, indicating that the model was successfully constructed.
- Lansoprazole administration for 3 days did not significantly reduce the ulcer area, while high, medium and low doses of ergosterol could significantly repair gastric ulcers caused by acetic acid and effectively treat gastric ulcers.
- the Glide software was used to study the docking of the compound ergosterol with the RoR ⁇ protein, and the results were compared with the RoR ⁇ /Cholesterol cocrystal results.
- Molecular docking of ergosterol and RoR ⁇ protein was performed, and the results are shown in Figure 3.
- a in Figure 3 is the binding mode of RoR ⁇ with the substrate small molecule Cholesterol (cholesterol) (PDBID: 1N83), and B is the binding mode of RoR ⁇ with the substrate small molecule Ergosterol.
- the left picture in A and B is the overall view, and the right picture is a partial view.
- the orange stick is a small molecule
- the blue cartoon is a protein
- the green dotted line represents the water bridge effect
- the gray dotted line represents the hydrophobic effect.
- the root mean square deviation of molecular dynamics simulation can reflect the movement process of the complex.
- the binding stability of RoR ⁇ protein and ergosterol was predicted using Amber18 software, and the results are shown in Figure 4.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention appartient au domaine technique des médicaments biologiques, et concerne spécifiquement l'utilisation d'ergostérol dans la préparation d'un médicament pour la prévention et le traitement d'ulcères gastriques. L'ergostérol de la présente invention peut favoriser la sécrétion de mucus gastrique, résister aux ulcères gastriques provoqués par l'alcool éthylique absolu, favoriser la rééducation des ulcères gastriques provoqués par l'acide acétique, et prévenir et traiter efficacement les ulcères gastriques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211239995.8 | 2022-10-10 | ||
CN202211239995.8A CN115531393A (zh) | 2022-10-10 | 2022-10-10 | 麦角甾醇在制备防治胃溃疡药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024078507A1 true WO2024078507A1 (fr) | 2024-04-18 |
Family
ID=84733050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/123828 WO2024078507A1 (fr) | 2022-10-10 | 2023-10-10 | Utilisation d'ergostérol dans la préparation d'un médicament pour la prévention et le traitement d'ulcères gastriques |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115531393A (fr) |
WO (1) | WO2024078507A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115531393A (zh) * | 2022-10-10 | 2022-12-30 | 深圳市中医院 | 麦角甾醇在制备防治胃溃疡药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552284A (zh) * | 2011-12-13 | 2012-07-11 | 陕西师范大学 | 麦角甾醇在制备肿瘤多药耐药逆转药物中的应用 |
CN109820954A (zh) * | 2019-03-29 | 2019-05-31 | 湖南新汇制药股份有限公司 | 一种中药组合物、制备方法及其在制备治疗慢性非萎缩性胃炎药物上的用途 |
CN113509496A (zh) * | 2021-07-29 | 2021-10-19 | 麦艳珍 | 一种假芝提取物及其制备方法和应用 |
CN115531393A (zh) * | 2022-10-10 | 2022-12-30 | 深圳市中医院 | 麦角甾醇在制备防治胃溃疡药物中的应用 |
-
2022
- 2022-10-10 CN CN202211239995.8A patent/CN115531393A/zh active Pending
-
2023
- 2023-10-10 WO PCT/CN2023/123828 patent/WO2024078507A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552284A (zh) * | 2011-12-13 | 2012-07-11 | 陕西师范大学 | 麦角甾醇在制备肿瘤多药耐药逆转药物中的应用 |
CN109820954A (zh) * | 2019-03-29 | 2019-05-31 | 湖南新汇制药股份有限公司 | 一种中药组合物、制备方法及其在制备治疗慢性非萎缩性胃炎药物上的用途 |
CN113509496A (zh) * | 2021-07-29 | 2021-10-19 | 麦艳珍 | 一种假芝提取物及其制备方法和应用 |
CN115531393A (zh) * | 2022-10-10 | 2022-12-30 | 深圳市中医院 | 麦角甾醇在制备防治胃溃疡药物中的应用 |
Non-Patent Citations (1)
Title |
---|
SATOH, KANAKO ET AL.: "The Effects of Kampo-Formulation and the Constituting Crude Drugs, Prescribed for the Treatment of Peptic Ulcer on H,K-ATPase Activity", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, PHARMACEUTICAL SOCIETY OF JAPAN, vol. 121, no. 2, 31 December 2001 (2001-12-31), pages 173 - 178, XP009553930, ISSN: 0031-6903 * |
Also Published As
Publication number | Publication date |
---|---|
CN115531393A (zh) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lever et al. | Treatment of pemphigus vulgaris with methotrexate | |
CN101287457B (zh) | Treprostinil用于治疗神经性糖尿病的足部溃疡的用途 | |
BR112020001285A2 (pt) | s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização | |
JP2961045B2 (ja) | 腸管粘膜増強促進剤 | |
WO2024078507A1 (fr) | Utilisation d'ergostérol dans la préparation d'un médicament pour la prévention et le traitement d'ulcères gastriques | |
CN104127859B (zh) | 多肽在制备治疗或预防类风湿性关节炎药物中的应用 | |
TW200425907A (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
Elliott | Timing treatment to the rhythm of disease: A short course in chronotherapeutics | |
TW200410683A (en) | Medicament for preventing and/or treating peripheral neuropathies | |
CN116098918A (zh) | 一种胞磷胆碱药物组合物及其用途 | |
RU2237475C1 (ru) | Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты) | |
US20090062338A1 (en) | Nitroxides for use in treating or preventing cardiovascular disease | |
US20110064813A1 (en) | Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet | |
RU2237470C1 (ru) | Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты) | |
CN114159435B (zh) | 附子灵在制备治疗关节炎药物中的应用 | |
EP3758702A1 (fr) | Traitement de l'oedème de quincke héréditaire | |
CN115531381B (zh) | 一种免疫调节化合物在制备治疗胰腺炎的药物中的应用 | |
CN114306332B (zh) | 塔拉萨敏在制备治疗关节炎药物中的应用 | |
CN110721310B (zh) | 一种药物组合物在制备治疗急性出血性脑损伤药物中的用途 | |
US20040192781A1 (en) | Method of administration for metoclopramide and pharmaceutical formulation therefor | |
US11819508B2 (en) | Miltefosine for the treatment of viral infections including covid-19 | |
CN112512526B (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
WO2005063253A1 (fr) | Composition medicinale pour le traitement de symptomes allergiques | |
CN110840869A (zh) | 二甲双胍在子宫内膜异位症药物中的应用 | |
WO2019135363A1 (fr) | Médicament thérapeutique pour des maladies impliquant principalement des lésions ténosynoviales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23876709 Country of ref document: EP Kind code of ref document: A1 |